Table 3.
BRM polymorphisms and progression-free survival in advanced stage non-small cell lung cancer
| Poly- morphism |
Category | PM Cohort (N=548) |
BR.24 Conventional Arm (N=109) |
BR.24 Experimental Arm (N=110) |
BR.24 All Patients (N=219) |
||||
|---|---|---|---|---|---|---|---|---|---|
| % | aHR (95%CI)1 | % | aHR (95%CI)2 | % | aHR (95%CI)2 | % | aHR (95%CI)2 | ||
| Wild-type | 29% | Reference | 30% | Reference | 27% | Reference | 28% | Reference | |
| Heterozygote | 48% | 1.57 (1.2–1.9) | 43% | 1.63 (0.9–3.0) | 49% | 1.45 (0.8–2.7) | 45% | 1.69 (1.1–2.6) | |
| BRM -741 | Homozygote | 23% | 2.05 (1.6–2.7) | 29% | 3.75 (1.9–7.4) | 25% | 2.25 (1.1–4.5) | 27% | 3.02 (1.9–4.8) |
| P value3 | <0.001 | <0.001 | 0.07 | <0.001 | |||||
| Minor allele frequency |
46% | 50% | 49% | 50% | |||||
| Wild-type | 34% | Reference | 28% | Reference | 30% | Reference | 29% | Reference | |
| Heterozygote | 44% | 1.22 (1.0–1.5) | 55% | 2.04 (1.1–3.7) | 46% | 1.10 (0.6–2.0) | 50% | 1.48 (1.0–2.2) | |
| BRM -1321 | Homozygote | 22% | 1.86 (1.5–2.4) | 18% | 3.37 (1.6–7.2) | 24% | 1.96 (1.0–3.9) | 21% | 2.57 (1.6–4.2) |
| P value3 | <0.001 | 0.006 | 0.07 | <0.001 | |||||
| Minor allele Frequency |
44% | 44% | 46% | 45% | |||||
| Combined Poly- morphisms |
Double Wild-type | 21% | Reference | 19% | Reference | 18% | Reference | 19% | Reference |
| No homozygote | 47% | 1.52 (1.2–1.9) | 46% | 1.71 (0.8–3.7) | 48% | 1.27 (0.6–2.7) | 47% | 1.62 (1.0–2.7) | |
| One Homozygote | 21% | 1.86 (1.4–2.5) | 24% | 2.87 (1.3–6.6) | 18% | 2.96 (1.2–7.0) | 21% | 3.11 (1.7–5.6) | |
| Two homozygotes | 12% | 2.71 (1.9–3.8) | 11% | 8.30 (3.2–21.9) | 15% | 2.08 (0.8–5.3) | 13% | 3.75 (1.9–7.3) | |
| P value3 | <0.001 | 0.001 | 0.02 | <0.001 | |||||
1
adjusted for sex, stage, ECOG performance status at diagnosis, number. of lines of systemic therapy received, and prior surgical resection of lung primary or site of oligometastases;
2
adjusted for sex, stage, ECOG performance status, weight loss, and time from diagnosis to randomization; in the “all patients” analysis, there was also stratification by treatment arm.
3
p-values are from Cox proportional hazard models comparing BRM polymorphisms and survival.
PM - Princess Margaret.